Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. (2021)

First Author: Kennedy NA

Attributed to: King's Health Partners Confidence in Concept funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1136/gutjnl-2021-324789

PubMed Identifier: 33903149

Publication URI: http://europepmc.org/abstract/MED/33903149

Type: Journal Article/Review

Volume: 70

Parent Publication: Gut

Issue: 10

ISSN: 0017-5749